Content about Merck

February 2, 2011
Decision Resources: Bydureon could promote weight loss among patients

Eli Lilly’s and Amylin Pharmaceuticals’ Type 2 diabetes drug, Bydureon, appears to work better at promoting weight loss than drugs made by Takeda and Merck, but it could face a challenger of its own.

January 28, 2011
Allegra's OTC switch could make it a big player in market

Though Schering-Plough’s — now Merck’s — Claritin and Johnson & Johnson’s Zyrtec product lines have dominated the over-the-counter antihistamine market, the big share of the prescription antihistamine market held by Sanofi-Aventis’ Allegra (fexofenadine hydrochloride) could give it a battering ram to bust in as well, thanks to the big break Sanofi got in the form of a Food and Drug Administration approval of an OTC switch for the drug.

January 12, 2011
Merck to develop biosimilars with Parexel

Drug maker Merck and drug industry services organization Parexel International will work together to develop biosimilars, the two said Wednesday.

January 11, 2011
FDA accepts application for extended-release Janumet

The Food and Drug Administration has accepted a regulatory approval application for a drug to treat Type 2 diabetes made by Merck, the drug maker said Tuesday.

January 6, 2011
Merck's hepatitis C drug granted priority review by FDA

The Food and Drug Administration granted priority review to an approval application for a hepatitis C drug made by Merck, the drug maker said Thursday.

December 23, 2010
FDA approves Merck's Gardasil for prevention of anal cancer

Merck on Wednesday announced that the Food and Drug Administration has approved Gardasil [human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant] for the prevention of anal cancer in males and females 9 to 26 years of age.

December 8, 2010
Decision Resources: J&J, Merck chemotherapy drugs will emerge as go-to second-line treatments

Chemotherapy drugs made by Johnson & Johnson and Merck will become the standard second-line treatment for ovarian cancer within the decade, replacing a treatment made by Bristol-Myers Squibb and generic versions, according to a new report by market research firm Decision Resources.

December 7, 2010
Reporters Notebook, Chain Pharmacy 12/13/10

Supplier News — Fera Pharmaceuticals has recently launched two new topical ointments. The New York-based company has developed Ilotycin (erythromycin) and Garamycin (gentamicin) ophthalmic ointments, both for the treatment of bacterial infections of the eye. “Our goal is simple: to keep more quality healthcare choices alive for the people who need them,” company co-founder Frank DellaFera said.





December 2, 2010
Merck to acquire SmartCells

Merck announced on Thursday it has inked a deal to acquire an insulin maker.

November 30, 2010
Merck's president steps in as new CEO

The president of drug maker Merck now will fill an additional position at the company: CEO.

November 21, 2010
Vytorin helps reduce cardiac events in chronic kidney disease patients

A cholesterol-lowering drug made by Merck appears to reduce the risk of heart attacks, strokes...

November 16, 2010
FDA advisory committee recommends expanded use of Gardasil

A Food and Drug Administration advisory committee has recommended expanded approval of a vaccine for...

November 16, 2010
Merck's cardiovascular drug improves cholesterol levels in patients during late-stage trial

Patients taking an investigational treatment for cardiovascular disease showed big improvements in cholesterol levels, according...

November 4, 2010
Merck releases results from phase-3 studies of hepatitis C drug

An investigative treatment for hepatitis C got strong results in patients who had failed previous...

October 27, 2010
Cigna, Merck Helps band together to stop diabetes

An insurance company and a patient assistance program have joined forces to improve medication adherence...

October 27, 2010
Decision Resources: More patients switch to Onglyza from Merck's Type 2 diabetes drugs

Many Type 2 diabetes patients who use the drug Onglyza (saxagliptin) switched to that drug...

October 14, 2010
Mylan's Hyzaar, Cozaar generics receive OK from FDA

The Food and Drug Administration has approved two generic drugs by Mylan for treating hypertension,...

October 12, 2010
Lupin gets green light from FDA for generic Hyzaar, Cozaar

Lupin Pharmaceuticals received regulatory approval last week for its generic antihypertensive agents, the drug maker...

October 12, 2010
Weight Watchers, Merck develop lifestyle management approach to fight obesity

A weight management services provider and a drug maker are teaming up to fight obesity....

September 29, 2010
Walgreens names SVP pharmaceutical development, market access

Walgreens announced Thursday that Jeffrey Berkowitz, a former SVP at drug maker Merck, has joined...

September 26, 2010
Suppliers take steps to address women’s needs

The opportunity within foot care may be even more skewed toward the female shopper than...

September 21, 2010
Drug offerings expand under Merck Helps programs

Merck is expanding its patient assistance program, the drug maker said Wednesday....

September 8, 2010
FDA approves expanded use of Saphris

Merck's supplemental drug applications for its atypical antipsychotic received approval from the Food and Drug...

August 11, 2010
Merck, Sesame Workshop give consumers 'food for thought'

Merck has teamed up with the nonprofit educational organization behind "Sesame Street" to develop a...

August 8, 2010
Merck’s boceprevir increases cure rate of hepatitis C, study finds

An investigational drug in late-stage clinical trials increased the cure rate in patients with hepatitis...

© 2013 Drug Store News. All Rights Reserved.